Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus olaparib before cystectomy in resectable urothelial bladder cancer
2017-002765-22Phase 2Active
- Sponsor
- SOGUG
- Start
- Jul 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and olaparib in bladder cancer, sponsored by SOGUG. Primary endpoint: Changes in gene expression and soluble markers. Started Jul 2018; status: active.
02
Drugs
durvalumabolaparib
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2017-002765-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002765-22.